Shares of Nightstar Therapeutics PLC Sponsored ADR (NASDAQ:NITE) have earned an average broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy rating.

Brokers have set a 12 month consensus price target of $23.00 for the company, according to Zacks. Zacks has also given Nightstar Therapeutics PLC Sponsored ADR an industry rank of 108 out of 265 based on the ratings given to its competitors.

Several analysts have recently weighed in on the company. Leerink Swann assumed coverage on Nightstar Therapeutics PLC Sponsored ADR in a research note on Monday. They set an “outperform” rating and a $25.00 target price for the company. BMO Capital Markets assumed coverage on Nightstar Therapeutics PLC Sponsored ADR in a research note on Monday. They set an “outperform” rating and a $30.00 target price for the company. Jefferies Group LLC assumed coverage on Nightstar Therapeutics PLC Sponsored ADR in a research note on Monday. They set a “buy” rating and a $25.00 target price for the company. Finally, Wedbush assumed coverage on Nightstar Therapeutics PLC Sponsored ADR in a research note on Monday. They set an “outperform” rating and a $19.00 target price for the company.

COPYRIGHT VIOLATION NOTICE: “Nightstar Therapeutics PLC Sponsored ADR (NITE) Receives Consensus Recommendation of “Strong Buy” from Analysts” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/24/nightstar-therapeutics-plc-sponsored-adr-nite-receives-consensus-recommendation-of-strong-buy-from-analysts.html.

Nightstar Therapeutics PLC Sponsored ADR (NASDAQ NITE) traded up 0.37% on Tuesday, reaching $18.77. The company had a trading volume of 40,552 shares. The stock’s market capitalization is $527.46 million. The firm has a 50-day moving average of $18.94 and a 200-day moving average of $18.94. Nightstar Therapeutics PLC Sponsored ADR has a 12 month low of $14.56 and a 12 month high of $24.93.

A hedge fund recently bought a new stake in Nightstar Therapeutics PLC Sponsored ADR stock. Nationwide Fund Advisors purchased a new position in Nightstar Therapeutics PLC Sponsored ADR (NASDAQ:NITE) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 62,300 shares of the company’s stock, valued at approximately $1,196,000. Nationwide Fund Advisors owned approximately 0.22% of Nightstar Therapeutics PLC Sponsored ADR as of its most recent filing with the Securities & Exchange Commission.

About Nightstar Therapeutics PLC Sponsored ADR

Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases.

Get a free copy of the Zacks research report on Nightstar Therapeutics PLC Sponsored ADR (NITE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Nightstar Therapeutics PLC Sponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics PLC Sponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.